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Prostate cancer (PCa) has a variable biology ranging from latent cancer to extremely aggressive tumors. Proliferative activities
of cancers may indicate their biological potential. A ﬂow cytometric assay to calculate maximum proliferative doubling times
(Tmax) of PCa in radical prostatectomy specimens after preoperative in vivo bromodeoxyuridine (BrdU) infusion is presented.
Only 4/17 specimens had tumors large enough for ﬂow cytometric analysis. The Tmax of tumors was similar and ranged from 0.6
to 3.6 months. Tumors had calculated doubling times 2- to 25-fold faster than their matched normal tissue. Variations in labeling
index and Tmax were observed within a tumor as well as between diﬀerent Gleason grades. The observed PSA doubling times
(PSA-DT) ranged from 18.4 to 32.0 months, considerably slower than the corresponding Tmax of tumors involved. While lack of
data for apoptotic rates is a limitation, apparent biological diﬀerences between latent versus aggressive PCa may be attributable to
variations in apoptotic rates of these tumors rather than their cell proliferative rates.
1.Introduction
In the year 2010, an estimated 217,000 men were expected
to be diagnosed with prostate cancer and 32,000 men to die
from this disease in the United States alone [1]. Prostatic
carcinoma (PCa) is a multifocal disease characterized by
marked heterogeneity of morphology as well as clinical
behavior. Nearly two-thirds of prostates contain multiple
cancer foci and the index or the largest tumor may not
necessarily determine the clinical outcome [2]. Autopsy
studies show that >50% of men age 50 and older have
histologic evidence of PCa [3]. These latent tumors are
histologically identical to aggressive PCa, but have not
progressed or became clinically evident in spite of their
histologicalsimilarities.AggressivePCamaybediﬀerentiated
from latent carcinoma based on volume, histologic grade,
and tumor doubling times [4, 5].
Histologic architectural grading is considered the main
prognostic tool for PCa [6]. However, the rate of prolifera-
tionandtumordoublingtimearealsoexpectedtohaveprog-
nostic relevance, and is key to understanding the biological
behavior of the tumor [5, 7, 8]. Research in this direction
has been limited due to diﬃculties of obtaining accurate cell
kinetic data in clinical settings. Accurate prediction of tumor
progression and patient survival is a challenging problem in
the clinical management of prostate cancer.
Knowledge of the biological behavior of latent and
aggressive tumors will assist clinicians in customizing the
treatment modalities. The current concept is that two major
categories of prostatic carcinomas exist: (1) those that
are latent and will not become clinically signiﬁcant in a
patient’s lifetime, and (2) clinically signiﬁcant tumors that
invade and have the potential to metastasize to distant sites2 Prostate Cancer
causing death. Prostate tumors of widely varying volumes
(range 0.001–35cc) can be found in a single prostatectomy
specimen [2]. It is often assumed that the “small” volume
tumors represent the slow growing latent ones while the
“large” volume tumors represent the fast growing clinically
signiﬁcant ones. There is no absolute volume that deﬁnes
“small” from “large” tumors. In addition, (a) small volume
tumors can be of high grade and (b) even low-grade, low-
volume carcinomas can be locally invasive [2]. While these
categories imply that such tumors would have remarkably
diﬀerent doubling times, no data exist that directly measure
this variable in appropriate tumors.
The method commonly used to measure proliferative
activity is evaluation of the S-phase fraction of the tumor
[9]. This is carried out with autoradiography, which has
certain limitations. Several investigators have used bromod-
eoxyuridine (BrdU) incorporation in ethanol ﬁxed prostate
biopsy tissue for the study of S-phase fraction or potential
doubling times of PCa [10, 11]. Potential doubling times
of 23–61 days were observed, but low labeling indices of
PCa were a confounding problem [11]. The present study
was undertaken to establish a technique to isolate nuclei
from formalin-ﬁxed paraﬃn-embedded radical retropubic
prostatectomy (RRP) specimens from patients who were
infused with BrdU prior to surgery. These specimens were
used to calculate maximum proliferative doubling times
(Tmax)o fP C ab yﬂ o wc y t o m e t r i ca n a l y s i s .
2.MaterialsandMethods
This study was approved by the Colorado Multiple Institu-
tional Review Board at the University of Colorado, Denver.
Between August 1999 and April 2002, written informed
consent was obtained from 17 RRP patients. The BrdU
solution of 25mg/mL was diluted into 250mL of normal
saline. The dose strength was 200mg per m2 of body surface
area. Between 20 and 48 hours prior to surgery, patients
received BrdU by IV administration over a 30min period.
The starting and ending times of infusion were recorded,
as well as the time of surgical removal of the prostate.
Excised prostates were ﬁxed in formalin, serially sectioned
into 4mm thick blocks, and paraﬃn-embedded for whole-
mount section preparation [12]. From the proximal surface
of each paraﬃn block, two 5-micron sections were cut.
One set of 5-micron sections from each block was stained
with hematoxylin and eosin (H&E) for routine histologic
examination by a pathologist. The remaining set of 5-micron
sections was used for immunohistochemical staining of
BrdU to conﬁrm nuclear incorporation. The boundary of
the Gleason grade of each tumor focus was outlined in ink
on H&E slides and transferred to acetate maps to generate
3D computer models of prostates as previously described
[13, 14]. Biomorphometric data including multifocality,
tumor volume, Gleason composition, capsule perforation
were extracted from the 3D computer models of each RRP
specimen [14]. Next, 3 sets of alternating 50-micron and 5-
micron sections were cut from the proximal surface of each
paraﬃn block containing the tumors of interest for doubling
time analyses. Each 5-micron section was again H&E stained
and mapped as described above. This was necessary to
conﬁrm the presence of tumors as they progressed through
the blocks, and to track shifting positions of these tumors.
Each 50-micron section was laid on top of the H&E slides
containing the outlined tumors. After tracing the edges of
the tumors onto the thick sections, tumors were excised
using a razor blade. The Gleason score of all tumors were
noted. Areas of relatively pure smooth muscle were also
marked and excised for use as normal diploid, slow-growing
controls for each patient’s prostate. We deﬁne proliferative
tumor doubling time Tmax as the theoretical maximum
doubling time assuming no cell death. The excised tissues
were processed as follows.
2.1. Deparaﬃnization and Rehydration. Tissue samples were
placed in Eppendorf centrifuge tubes and paraﬃnw a s
removed by incubating for 3min with Americlear (Richard-
Allan Scientiﬁc, Kalamazoo, MI). Samples were centrifuged
for 2min at 389×g to gently pellet the tissue, and Americlear
was removed. The washes with Americlear were repeated
twice more. Residual Americlear was removed from the
tissue with 2 changes of 100% ethanol, vortexing gently,
and incubating 3min each prior to centrifugation. Tissue
was resuspended in fresh 100% ethanol (0.5mL), and
distilledwaterwasaddeddropwise,tappingthetubebetween
drops, to slowly rehydrate to a ﬁnal volume of 1mL
(note: if tissue contains residual Americlear, the supernatant
becomes cloudy upon the addition of water, and requires
additional ethanol washes before attempting rehydration).
After centrifugation, tissue was washed once in distilled
water, centrifuged again, and supernatant removed.
2.2. Pepsin Digestion. Samples were resuspended in 1mL
0.5% pepsin in 0.9% NaCl (pH 1.5), and incubated for
30min at 37◦C, vortexing after 15min. After centrifugation
to pellet cells, the supernatant was removed and fresh pepsin
added. The suspension was pipetted to break up clumps of
cells, and then incubated for 30min at 37◦C. After vortexing,
the samples were allowed to continue to digest overnight
at 4◦C. Cells were then centrifuged and washed once with
phosphate buﬀered saline (PBS) with pH 7.4 and once with
distilled water, leaving approximately 150μL of supernatant
on each pellet prior to tapping to resuspend.
2.3. Acid Denaturation of DNA. While slowly vortexing each
sample, 1mL of 2M HCl with 0.5% triton X-100 was added
dropwise.Ifaddedtooquickly,nucleimaylyse.Sampleswere
then incubated at room temperature for 30min, centrifuged
at389×gfor5min, and neutralizedwith1mL 0.1Msodium
borate, pH 8.5. PBS (1mL) was added to each tube, and the
suspension was run through 35μM cell strainers to remove
undigested debris. Cells were then centrifuged and washed
once in PBS with 0.1% bovine serum albumin and 0.5%
Tween-20 (PBS-AT).Prostate Cancer 3
2.4. Antibody Staining. After removing most of the super-
natant from each sample, the volume in each tube was
adjustedtoexactly182.5μLwithPBS-AT,and87.5μLofeach
weretransferredtonewtubesforpairednonspeciﬁccontrols.
For BrdU detection, 5μL mouse monoclonal anti-BrdU
antibody (clone PrB1, FITC-labeled, Phoenix Flow Systems
Inc., San Diego, CA) was added to one set of tubes, yielding
a ﬁnal antibody concentration of 12.5μg/mL in 100μL. To
measure nonspeciﬁc antibody staining, the remaining tubes
received 12.5μL FITC-labeled mouse IgG1 (clone Dak-G01,
Dako Corp., Carpenteria, CA) to yield 12.5μg/mL in 100μL.
After mixing gently, tubes were incubated for either 40min
at room temperature in the dark (mixing after 20min),
or overnight at 4◦C in the dark (mixing after 1 hour).
Samples were washed 3 times in PBS-AT, incubating for 20–
30min at room temperature each time before centrifuging.
These incubations are critical to allow diﬀusion of unbound
antibody from the denatured DNA. The ﬁnal cell pellet was
resuspended in 0.4mL PBS with 10μg/mL propidium iodide
and 0.05mg/mL DNase-free RNase A. Samples were then
incubated for 1–3 hours at 4◦C (protected from light) to
allow intercalation of propidium iodide and degradation of
any remaining RNA.
2.5.FlowCytometricAnalyses. Sampleswereanalyzedforred
and green ﬂuorescence as ﬁrst reported by Begg et al. [9]o n
a Coulter XL ﬂow cytometer (Coulter-Beckman, Fullerton,
CA). Listmode data were obtained using 50,000 cells for
most samples, and at least 10,000 cells for small tumor
specimens. All initial listmode ﬁles were more carefully
analyzed subsequently using Cytomation Summit software
(CytomationInc.,FortCollins,CO)toﬁne-tuneallgatesand
statistical regions. Three independent analyses of the same
listmode data were done for each sample, to account for
diﬀerences in how gates and statistical regions were drawn.
The following values were collected from the ﬂow cytometric
histograms.
Histogram 1 (Figure 1(a)). Doublet discrimination was at-
tempted by gating tightly on the G0/G1, S-phase, and G2/M
populations. This was likely to exclude hypertetraploid cells
if they existed, as well as doublets.
Histogram 2 (Figure 1(b)). Four diﬀerent measurements
were obtained from this histogram: FG1, FG2/M, FL, and
LI. FG1 estimates the degree of red ﬂuorescence (measured
by mode rather than mean) of the BrdU-negative G0/G1
population. BrdU-positive cells are excluded from this mea-
surement. FG2/M measures the red ﬂuorescence (mode) of
the BrdU-negative G2/M population. FL measures the mean
red ﬂuorescence of the BrdU-positive cells in S-phase and
G2/M (exclude G0/G1). LI is the labeling index, measuring
the percentage of all BrdU-positive cells.
The potential doubling times for each sample were then
calculated using Begg’s et al. original formulas [9], the ﬂow
cytometric values, and the length of time between the BrdU
infusion and the surgical removal of the prostate (Tc);
Relative movement:
RM =
[FL −FG1]
[FG2/M − FG1]
,
Length of S-phase:
Ts =
[0.5(Tc)]
[RM −0.5]
,
Maximum proliferative doubling time:
Tmax =
λ(Ts)
LI
where λ ≈ 1.
(1)
2.6. Immunohistochemical Staining of BrdU and Ki-67.
Two sets of consecutive 5-micron sections from paraﬃn-
embedded blocks of RRP specimens were used in immuno-
histochemical (IHC) staining for BrdU and Ki-67 [15]. First
set of 5-micron sections was baked in a 60◦Co v e nf o r
1 hour. Rats infused with BrdU were sacriﬁced and the
intestine harvested to serve as the tissue controls. After
deparaﬃnization, antigen retrieval was performed in BORG
solution, pH 9.5 (Biocare Medical, Concord, CA) for 5min
in the Decloaking chamber pressure cooker (Biocare). Slides
were left on the countertop for 5–10min to cool down at
roomtemperature.Endogenousperoxidasewasblockedwith
aqueous3%hydrogenperoxidefor10min.Slideswererinsed
inAPKwash(1Xsolution,VentanaMedicalSystems,Tucson,
AZ). All reactions were performed at room temperature.
Test slides and positive control were incubated in anti-BrdU,
1:10, (in-situ kit, BD Biosciences, San Diego, CA) for 1 hour
in a humidiﬁed chamber. A negative control was incubated
with mouse ascites, 1:500, (Sigma Aldrich, St. Louis, MO).
Slides were rinsed 3 times in APK for 5min each time,
and then further incubated in Streptavidin-HRP supplied
from the in-situ kit for 30min in a humidiﬁed chamber.
A mixture of 1mL DAB (diaminobenzidine) buﬀer and 1
drop DAB chromogen was incubated on the slides for 5min.
Afterwards, DAB buﬀer was rinsed oﬀ with deionized water.
Slides were equilibrated in aqueous 1% acetic acid, stained
in 0.02% light green SF yellowish for 5 dips, and returned
to the acetic acid bath to set the color. Finally, slides were
dehydrated in graded alcohols, cleared with xylene, and
mounted with synthetic resin.
IHC staining for Ki-67 was performed on the second set
of 5-micron sections. A mouse antihuman antibody against
Ki-67 (DAKO, Carpinteria, CA M7240; 1:300) was used to
measure proliferation in the tissue sections. Antigen retrieval
in BORG solution, pH 9.5 (Biocare Medical, Concord, CA,
BDS1000G1) was performed for 5 minutes in the Decloaker
pressure cooker (Biocare) at 125◦C (22psi). All incubations
were accomplished by the Ventana NexES (Ventana Medical
Systems, Tucson, AZ) immunostainer at 37◦C. A Ventana
I-VIEW DAB detection kit was used to detect the anti-
gens through universal secondary antibodies, streptavidin-
horseradish peroxidase enzyme, and DAB visualization.4 Prostate Cancer
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Figure 1: (a) Histogram 1: auxiliary peak red ﬂuorescence versus red ﬂuorescence, and (b) histogram 2: BrdU-FITC green ﬂuorescence
versus propidium iodide red ﬂuorescence.
The sections were removed from the immunostainer and
counterstained in light green sf yellowish (Sigma-Aldrich,
St. Louis, MO, L1886-25G; 0.04%w/v) for 10 seconds,
q u i c k l yd e h y d r a t e di ng r a d e da l c o h o l s ,c l e a r e di nx y l e n e ,a n d
mounted with synthetic resin. BrdU and Ki-67 LI using IHC
staining were determined by counting number of positively
stained cells per 1000 cells.
3. Results
The mean age of 17 patients was 57.6 ± 5.17 years (range 44–
66years)andthemedianagewas58years.Themeanprostate
gland volume was 34.39 ± 10.45cc (range 17.17–54.34cc),
the mean tumor volume was 1.62 ± 3.34cc (range 0.001–
8.663cc), and the mean number of separate tumors was 2.6
(range 1–8). Only 4/17 prostates had tumors large enough
for ﬂow cytometric analysis. Tumor biomorphometry data
of four prostates used in ﬂow cytometric analyses are
summarized in Table 1. The LI for BrdU and Ki-67 by IHC
stainingaregiveninTable 2.ThemeanLIforBrdUandKi-67
was 2.14 ± 1.94% and 6.18 ± 4.27, respectively. There was no
signiﬁcant correlation between BrdU and Ki-67 LI (Pearson
correlationcoeﬃcientR=0.41,P = 0.16).Figure 2illustrates
aphotomicrographofGleasonpattern3PCawhereBrdUhas
beenincorporatedintotheDNAof5–7%ofdividingS-phase
cancer cells. A typical distribution of BrdU-incorporated
cell nuclei within Gleason pattern 4 glands is illustrated
in Figure 3. Table 3 summarizes ﬂow cytometry data for LI
and Tmax of prostate tumors from four prostates. The mean
LI and Ts of prostate tumors and matched smooth muscle
controls (in parenthesis) were 5.3 ± 3.1% (2.5 ± 0.28%) and
58 ± 27hrs (224 ± 318hrs), respectively. Tmax of smooth
muscle in diﬀerent patients varied from 99 to 636 days. Tmax
foralltumorsrangedfrom19to108days(0.6to3.6months)
and they doubled between 2-fold and 25-fold faster than
their matched smooth muscle controls.
The large tumor PBr4-T1 doubled approximately 2-3-
times faster than the small tumor PBr4-T2 depending on the
block from which the large tumor samples were excised. For
example, T1 doubled approximately twice as fast as T2 when
sampled from Block H but it doubled 3-times faster when
sampled from Block F. Similar variations in the doubling
rates were observed in the large tumor PBr18-T2. In this
c a s e ,G l e a s o np a t t e r n s3a n d4p o r t i o n so fT 2i nB l o c k sB
and D doubled twice as fast as the Gleason pattern 4 portion
of the same tumor in Block D. However, the small tumor
PBr18-T1 in Block B doubled 1.5–3-times faster than large
tumorT2inBlocksBandD.Intheremainingtwospecimens
(PBr6, PBr16), only the Tmax of one large tumor each was
reported since we did not have suﬃcient cell count to run
ﬂowcytometricanalysisofcorrespondingsmalltumors.Also
in PBr16-T1, analysis was limited to tumors excised from
only two blocks (E and G). LI for smooth muscle in diﬀerent
specimens remained relatively constant but it varied among
diﬀe r e n tt u m o r sa sw e l la sw i t h i nt u m o r s .P S AD o u b l i n g
times (PSA-DT) of these patients were also calculated [16]
andarepresentedinTable 4 withcorrespondingaverageTmax
foreachtumor.Eveninthissmallsampleoftumorsanalyzed,
Tmax values of tumors involved were considerably faster than
corresponding PSA-DT observed for each patient.
4. Discussion
We have developed an assay to use in vivo BrdU infused,
formalin-ﬁxed, paraﬃn-embedded RRP specimens for TmaxProstate Cancer 5
Table 1: Tumor biomorphometric data.
Specimen Number of tumors Gleason score Tumor volume, cc Volume of Gleason 3, cc Volume of Gleason 4, cc
PBr4
1 3 + 3 2.823 2.823
2 3 + 3 0.121 0.121
3 3 + 3 0.022 0.022
4 3 + 3 0.006 0.006
5 3 + 3 0.015 0.015
6 3 + 3 0.001 0.001
PBr6
1 3 + 3 0.656 0.656
2 3 + 3 0.009 0.009
3 3 + 4 0.037 0.025 0.012
4 3 + 3 0.028 0.028
PBr18
1 3 + 3 0.015 0.015
2 3 + 4 0.842 0.736 0.098
3 3 + 3 0.755 0.755
4 3 + 4 0.023 0.009 0.014
5 3 + 3 0.021 0.021
PBr16 1 3 + 4 7.642 7.511 0.131
2 3 + 3 0.022 0.022
Table 2: BrdU and Ki-67 LI by IHC staining of consecutive 5-
micron sections.
Specimen and block
with tumor BrdU LI % by IHC Ki67 LI % by IHC
PBr1-E 3.3 4.6
PBr2-C 0.4 7.5
PBr3-D 1.2 0.9
PBr6-E 1.1 2.8
PBr7-E 3.5 8.9
PBr8-C 1.3 3.1
PBr9-G 0.1 9.5
PBr10-C 2.2 5.0
PBr12-E 5.0 7.9
PBr14-D 0.4 2.1
PBr15-C 0.7 1.9
PBr16-D 6.5 10.6
PBr19-C 2.1 15.6
evaluation by ﬂow cytometric analysis. This is the ﬁrst report
to establish an in vivo BrdU incorporation technique in
formalin-ﬁxed prostate tumors and the calculation of Tmax
in patients with prostate cancer. This protocol appears to
accurately estimate doubling times of tissues with rat intes-
tinecontrolsbeingthefastest(24–48hr)andhumanprostate
smooth muscle being the slowest. Our data demonstrate that
it is possible to study proliferative activity of prostate tumors
by direct measurement of Tmax. Our data also suggest there
are variations in Tmax calculations within a tumor depending
on where the tumor was sampled. Similar variations in Tmax
were observed within a speciﬁc Gleason grade as well as
among diﬀerent Gleason grades. This variability observed
in the proliferative activity of prostate tumors in regard to
Figure 2: Gleason pattern 3 carcinoma with BrdU incorporated
into the DNA of dividing cells (magniﬁcation 40X).
size and Gleason pattern may be due to (a) block-to-block
variations in ﬁxation, and (b) the heterogeneous nature of
cancer cells and the multifocality of this particular disease.
Since we used the average value of Tmax calculated from three
consecutive samples for each tumor section, contributions
due to variability of the methodology should be small
compared to other factors. Immunohistochemical staining
conﬁrmedthatBrdUhadbeenincorporatedintotheDNAof
dividing PCa cells. Each tumor had 2% or more labeled cells,
suﬃcient for ﬂow cytometric analysis and Tmax calculations.
Out of 17 patients, we were able to analyze tumors of
only four patients. The majority of the tumors were small
(<0.1cc) and hence we were unable to cut a suﬃcient num-
ber of 50-micron thick tissue sections for ﬂow cytometric
analysis.Severallargetumorswereusedtodevelopandreﬁne
the ﬂow cytometric protocol. This small sample size is one
limitation of our study.
Nemoto et al. studied the S-phase fraction of biopsies
collectedfrompatientswithinvivoBrdUincorporation[10].
The biopsies were ﬁxed with ethanol, embedded in paraﬃn,
sectioned, and stained by an indirect immunoperoxidase6 Prostate Cancer
Table 3: Proliferative tumor doubling times of prostatic carcinoma.
Specimen Tumor Tumor volume, cc Block with tumor Gleason pattern∗ BrdU LI % by ﬂow cytometry Tmax, days Growth rate∗∗
PBr4
T1 2.823
T1-F 3 9.1 ± 0.9 25.7 ± 4.0 25X
T1-G 3 4.2 ± 0.5 41.5 ± 3.9 15X
T1-H 3 3.7 ± 0.3 48.0 ± 4.0 13X
T2 0.121 T2-C 3 3.4 ± 0.3 97.9 ± 7.8 7X
Muscle — — — 2.6 ± 0.0 636.2 ± 135.1 —
PBr6
T1 0.656 T1-B 3 3.2 ± 0.3 50.7 ± 1.5 2X
T1-C 3 3.1 ± 0.3 51.1 ± 5.7 2X
Muscle — — — 2.3 ± 0.4 98.6 ± 12.7 —
PBr18
T1 0.015 T1-B 3 5.7 ± 2.2 36.6 ± 7.3 6X
T2 0.842
T2-B 3 & 4 5.2 ± 1.1 52.2 ± 7.0 4X
T2-D 4 3.8 ± 0.9 108.1 ± 14.8 2X
T2-D 3 & 4 3.7 ± 0.7 57.4 ± 8.9 4X
T3 0.755 T3-D 3 13.6 ± 1.7 17.3 ± 2.6 13X
T3-E 3 4.9 ± 0.7 73.5 ± 9.1 3X
Muscle — — — 2.7 ± 0.1 221.7 ± 41.8 —
PBr16
T1 7.642 T1-E 3 2.0 ± 0.1 60.0 ± 4.8 2X
T1-G 4 7.8 ± 0.2 19.0 ± 1.7 7X
Muscle — — — 1.4 ± 0.2 137.0 ± 33.0 —
∗Gleason pattern: Gleason pattern of the excised tumor section for a given block.
∗∗Growth rate: Tmax of matched muscle/Tmax of tumor.
Table 4: Proliferative tumor doubling time versus PSA doubling
time.
Specimen and Tumor number
Tumor
volume
(cc)
Average
Tmax
∗
(months)
PSA doubling
Time
(months)
PBr4 T1 2.823 1.28 18.4
T2 0.121 3.26
PBr6 T1 0.656 1.70 22.8
PBr18
T1 0.015 1.22
27.8 T2 0.842 2.42
T3 0.755 1.51
PBr16 T1 7.642 1.32 32.0
∗is the average of Tmax calculated when tumor is found in more than one
paraﬃnb l o c k .
method using anti-BrdU monoclonal antibody. LI was
determined by counting the number of labeled cells. They
demonstrated an average LI of Gleason grade 3, 2, and
1 PCa to be 4.37 ± 0.48%, 2.41 ± 0.49%, and 1.36 ±
0.39%, respectively. Haustermans et al. also used ethanol
ﬁxed biopsy tissue from patients with in vivo incorporation
and reported potential doubling times from 23 to 61 days in
prostate tumors among ﬁve patients [11].
In our study, the mean BrdU LI by IHC staining was
2.14 ± 1.94% and by ﬂow cytometry 5.3 ± 3.1%. Ki-67
LI also measures cell proliferation. Nagao et al. found that
prostate cancer patients with PSA > 4h a dam e a nK i - 6 7
LI of 10.5 ± 2.2% [15]. The mean Ki-67 LI in our study
was 6.18 ± 4.27%. However, we did not ﬁnd any signiﬁcant
correlation between BrdU and Ki-67 LI. Since Tmax depends
Figure 3: Distribution of BrdU incorporated cell nuclei within
Gleason pattern 4 glands (magniﬁcation 100X).
on both Ts and LI (given by the formula Tmax = λ(Ts)/LI),
it is not possible to establish a direct correlation between
Tmax and LI alone. Consequently, LI of BrdU either by IHC
or by ﬂow cytometry alone are not accurate predictors of
Tmax and hence the biological potential of tumors. Our
results suggest that the measurement of BrdU LI and Tmax
calculationsbyﬂowcytometryusingformalin-ﬁxedparaﬃn-
embedded prostates may prove to be a quantitative assay of
the biological potential of individual tumors.
Schmid et al. found that PSA-DT were faster in patients
with higher stages and grades [17, 18]. They found 20/28
clinically organ-conﬁned cancers doubled at rates exceeding
4 years and concluded that prostate tumors have a constant
(log-linear) growth rate that is very slow. It should be
noted that in men with PSA levels between 4 and 10 with
relatively small volume clinically localized tumors, the PSA
levels do not correlate well with the tumor volume which
potentially indicates that PSA levels in these patients mayProstate Cancer 7
not be driven by the cancer cells themselves, but rather by
other benign processes in the prostate such as inﬂammation
and/or BPH [19]. In our study, total tumor volume of each
prostate selected for ﬂow cytometry was relatively large and
hence PSA levels do correlate with tumor volume. PSA-
DT for our patients were 18.4–32 months (552–960 days)
[16]. This “apparent” slow growth rate of PCa tumors
indirectly evaluated from PSA doublings may be attributed
toconcomitantcelldeath(apoptosis).Therefore,apoptosisis
animportantdeterminantofPSA-DT.EventhoughPCacells
are dividing at a faster rate, a relatively high apoptotic rate
may result in a much slower net growth rate. However, there
are no direct methods available to measure in vivo apoptotic
rates of PCa as cells that undergo apoptosis are removed
from the gland. Nevertheless, apparent biological diﬀerences
between latent versus aggressive PCa may be attributable to
variations in cell death rates of these tumors more than to
their cell proliferative rates.
5. Conclusion
A ﬂow cytometric assay using in vivo BrdU-infused, forma-
lin-ﬁxed paraﬃn-embedded RRP specimens was developed
to determine Tmax of prostate tumors. Tmax of 4 PCa tended
to be similar regardless of tumor volume or histologic grade.
However, Tmax of tumors were faster than observed PSA-DT
of corresponding patients. While lack of data for apoptotic
rates is a limitation of this study, relative variations in
apoptotic rates may make the diﬀerence between latent and
aggressivePCa,ratherthanTmax.Futurestudiesneedtofocus
on tumor proliferative doubling times as well as apoptotic
rates to better understand biological diﬀerences of latent
versus aggressive prostate cancer.
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